Immunohistochemistry Stains

The ARUP Immunohistochemistry Laboratory performs more than 175 stains on formalin-fixed, paraffin-embedded tissues/cellblocks. These stains are used to detect the presence, abundance, and localization of specific proteins to aid in determining the direction of differentiation in neoplasms with similar morphology as well as to provide prognostic or therapeutic information, among other applications.

This lab is pathologist oriented, providing a stain and return service only, without interpretation, to our client pathologists to assist in their diagnostic studies. Most stains are returned the next day. The available stains are listed under the Stain and Return Immunohistochemistry tab. If interpretation is needed, please order a consultation.

To order a surgical pathology consultation, please use test code 2013263 Consultation, Surgical Pathology or 2013258 Consultation, Hematopathology. For more information, call (801)581-2507. Please include pertinent clinical history and surgical pathology report.

The Immunohistochemistry Laboratory has a menu of immunohistochemistry tests for which we will provide interpretation by one of our ARUP faculty pathologists. A list of these tests can be found under the Immunohistochemistry Tests tab. The ARUP Immunohistochemistry Laboratory is an NSABP-approved laboratory for the testing of breast markers.
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Test # Test Name Test Keywords Test Description
2003472 Breast 2 (GCDFP-15) by Immunohistochemistry Tumor Markers, Mammary carcinoma, Extramammary Pagets disease
  • Gross cystic disease fluid protein-15
  • Produced by cells with apocrine function
  • Differentiation marker for mammary carcinomas
  • Extramammary Paget disease
2003445 Breast Carcinoma b72.3 by Immunohistochemistry Mesothelioma, Lung Cancer, Tumor Markers, Adenocarcinoma, Breast carcinoma Tumor-associated glycoprotein (TAG.72):
  • Recognizes tumor-associated oncofetal antigen
  • Aids in identifying adenocarcinomas and breast carcinomas
2003547 CD30 (Ki-1) by Immunohistochemistry Hodgkin lymphoma, T-cell lymphoma, B-Cell Lymphomas, Tumor Markers, solitary fibrous tumor, sarcoma
  • Ki-1 positive lymphoma
  • Ber-H2
  • Expressed by activated B- and T-lymphocytes, Reed-Sternberg cells
  • Aids in identifying Hodgkin lymphoma, lymphomatoid papulosis, anaplastic large cell lymphoma, some peripheral pleomorphic T-cell lymphomas (both HTLV-1 positive and negative) including those of angioimmunoblastic type and Lennert type and embryonal carcinoma
2003514 CD5 by Immunohistochemistry T-Cell Lymphomas, B-Cell Lymphomas, Tumor Markers
  • Expressed in T-lymphocytes, thymocytes and subset of B-lymphocytes in lymph nodes
  • Aids in identifying T-cell leukemias, most B-cell chronic lymphocytic leukemias (B-CLL) and mantle cell lymphomas/T- and B-cell lymphomas
2010168 DOG1 by Immunohistochemistry
  • Shown to be highly specific and sensitive in the diagnosis of GIST
  • Approximately 4–15% of GIST will stain weakly or be negative for CD117 by IHC; in the vast majority of these cases, DOG1 is expressed by IHC.
2004516 Estrogen Receptor (ER) by Immunohistochemistry Ovarian Cancer, Breast Cancer, Tumor Markers Estrogen receptor-alpha:
  • Prognostic for breast cancer
  • Predictive for response of breast cancers to hormonal therapy
  • Differentiates endocervical from endometrial adenocarcinomas
2003914 HBME-1 (Mesothelial Cell) by Immunohistochemistry Mesothelioma, Thyroid Cancer Anti-mesothelial cell:
  • Has been demonstrated to immunostain the membrane and cytoplasm of normal plural and peritoneal mesothelial cells and of neoplastic epithelial mesothelioma cells.
  • Although both the membrane and cytoplasm of epithelial mesothelioma cells stain positive, the thick membrane staining pattern is found to be a more diagnostically useful marker of malignant mesothelioma.
2003923 Hepatocyte Specific Antigen (HSA) by Immunohistochemistry Hepatocellular Carcinoma Hep Par-1:
  • Expressed in hepatocytes
  • Differentiates hepatocellular carcinomas and metastatic carcinomas
  • Differential diagnosis of hepatocellular carcinomas, cholangiocarcinomas, and hepatoblastomas
2003969 Inhibin by Immunohistochemistry Brain Tumors, Ovarian Cancer
  • Expressed in Sertoli cells, granulosa cells, and prostate, brain, and adrenal cells
  • Present in sex-cord stromal tumors (including Sertoli cell tumors), adrenocortical tumors, placental and gestational trophoblastic lesions, granular cell tumors of gallbladder and extrahepatic bile ducts, and some carcinomas
2004076 P504S (AMACR) by Immunohistochemistry Prostate Cancer
  • Prostate
  • α-Methylacyl-CoA Racemase (AMCAR)
  • Specific for prostate adenocarcinomas
  • Detected in two premalignant lesions: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia
2004073 p63 by Immunohistochemistry Bladder Cancer, Lung cancer, small cell lung cancer, neuroendrocrine
  • Differentiates prostatic adenocarcinoma and benign prostatic tissue.
  • Also distinguishes poorly differentiated squamous cell carcinoma from small cell carcinoma or adenocarcinoma.
2004079 Prostatic Acid Phosphatase (PAP) by Immunohistochemistry Prostate Cancer Prostate acid phosphatase:
  • Reacts with prostatic epithelial cells and hyperplastic prostate
  • Present in carcinomas of the prostate and metastatic cells of prostate carcinoma, bladder carcinomas, and carcinoid tumors
2004124 Renal Cell Carcinoma (RCC) Antigen by Immunohistochemistry Renal cell carcinoma:
  • Localized along the brush border of the pars convolute and pars recta segments of the proximal tubule and focally along the luminal surface of Bowman?s capsule.
  • Of normal tissues, is also localized along the luminal surface of breast lobules and ducts, the luminal surface of the epididymal tubular epithelium, within the cytoplasm of the parathyroid parenchymal cells and focally within the colloid of thyroid follicles.
2010688 TFE3 by Immunohistochemistry
  • Indicated in the clinical diagnosis of malignancy as an aid in the recognition of Xp11 translocation in renal cell carcinoma and alveolar soft-part sarcoma.
  • Also reported in transitional renal cell carcinoma, lung adenocarcinoma, papillary thyroid carcinoma, melanoma, and mesothelioma.